| Melanie V Alpeche Albert, FNP | |
|
2895 Lewis Ln, Paris, TX 75460-9331 | |
| (972) 203-3600 | |
| Not Available |
| Full Name | Melanie V Alpeche Albert |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 19 Years |
| Location | 2895 Lewis Ln, Paris, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801844741 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Paragon Pain And Rehabilitation Llp | 2466616032 | 15 |
| Prmc Healthcare Group, Inc. | 6406919901 | 40 |
News Archive
A University of Arkansas for Medical Sciences research team led by Vladimir Zharov, Ph.D., D.Sc., has demonstrated the ability to detect and kill circulating tumor cells in the blood using a noninvasive device called Cytophone that integrates a laser, ultrasound and phone technologies.
Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children. Scientists hope the finding could lead to an effective therapy to inhibit the expression of this gene.
Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
› Verified 9 days ago
| Entity Name | Prmc Healthcare Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457514648 PECOS PAC ID: 6406919901 Enrollment ID: O20090109000317 |
News Archive
A University of Arkansas for Medical Sciences research team led by Vladimir Zharov, Ph.D., D.Sc., has demonstrated the ability to detect and kill circulating tumor cells in the blood using a noninvasive device called Cytophone that integrates a laser, ultrasound and phone technologies.
Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children. Scientists hope the finding could lead to an effective therapy to inhibit the expression of this gene.
Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
› Verified 9 days ago
| Entity Name | Khalid Shafiq, M.d. , P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588979363 PECOS PAC ID: 2466641998 Enrollment ID: O20110113000873 |
News Archive
A University of Arkansas for Medical Sciences research team led by Vladimir Zharov, Ph.D., D.Sc., has demonstrated the ability to detect and kill circulating tumor cells in the blood using a noninvasive device called Cytophone that integrates a laser, ultrasound and phone technologies.
Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children. Scientists hope the finding could lead to an effective therapy to inhibit the expression of this gene.
Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
› Verified 9 days ago
| Entity Name | Paragon Pain & Rehabilitation Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780958777 PECOS PAC ID: 2466616032 Enrollment ID: O20120611000491 |
News Archive
A University of Arkansas for Medical Sciences research team led by Vladimir Zharov, Ph.D., D.Sc., has demonstrated the ability to detect and kill circulating tumor cells in the blood using a noninvasive device called Cytophone that integrates a laser, ultrasound and phone technologies.
Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children. Scientists hope the finding could lead to an effective therapy to inhibit the expression of this gene.
Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melanie V Alpeche Albert, FNP Po Box 1200, Colleyville, TX 76034-1200 Ph: (722) 033-6009 | Melanie V Alpeche Albert, FNP 2895 Lewis Ln, Paris, TX 75460-9331 Ph: (972) 203-3600 |
News Archive
A University of Arkansas for Medical Sciences research team led by Vladimir Zharov, Ph.D., D.Sc., has demonstrated the ability to detect and kill circulating tumor cells in the blood using a noninvasive device called Cytophone that integrates a laser, ultrasound and phone technologies.
Virginia Commonwealth University researchers have identified a gene that may play a key role in regulating tumor progression in neuroblastoma, a form of cancer usually found in young children. Scientists hope the finding could lead to an effective therapy to inhibit the expression of this gene.
Scrip, a leading global pharmaceutical and biotech news organization, honored Abbott with two 2010 Scrip Awards for its business excellence and strong management.
Chronic kidney disease (CKD) is caused by diabetes and hypertension. In 2017, the global prevalence of CKD was 9.1 percent, which is approximately 700 million cases.
Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.
› Verified 9 days ago
Kimberly Smith, MSN, APRN, FNP-BC Pain Medicine Medicare: Accepting Medicare Assignments Practice Location: 2895 Lewis Ln, Paris, TX 75460 Phone: 972-203-3600 |